Patents by Inventor Bjoern Hock

Bjoern Hock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10808032
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: October 20, 2020
    Assignee: Ablynx NV
    Inventors: Christine Knuehl, Bjoern Hock, Robert Hofmeister, Gerald Beste, Hilde Adi Pierrette Revets, Frank Kamiel Delphina Verdonck, Sigrid Godelieve Victor Cornelis
  • Patent number: 10676733
    Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 9, 2020
    Assignee: Merck Patent GmbH
    Inventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
  • Publication number: 20190367620
    Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.
    Type: Application
    Filed: November 21, 2017
    Publication date: December 5, 2019
    Inventors: CHRISTEL IFFLAND, CHRISTINA ESDAR, XINYAN ZHAO, QI AN, JOHANNES YEH, GANG HAO, LARS TOLEIKIS, VANITA SOOD, DAVID NANNEMANN, ROBIN LYTLE, BJOERN HOCK
  • Publication number: 20190023796
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Application
    Filed: February 14, 2018
    Publication date: January 24, 2019
    Applicant: Ablynx NV
    Inventors: Christine KNUEHL, Bjoern HOCK, Robert HOFMEISTER, Gerald BESTE, Hilde Adi Pierrette REVETS, Frank Kamiel Delphina VERDONCK, Sigrid Godelieve Victor CORNELIS
  • Patent number: 10183994
    Abstract: The invention relates to anti-TNF? antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF? antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ralf Guenther, Stefan Becker, Laura Rhiel, Bjoern Hock, Christian Schroeter
  • Patent number: 10138477
    Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterization.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 27, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Ralph Guenther, Bjoern Hock, Stefan Becker, Laura Rhiel
  • Publication number: 20180298374
    Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.
    Type: Application
    Filed: October 27, 2015
    Publication date: October 18, 2018
    Applicant: Merck Patent GmbH
    Inventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
  • Publication number: 20180171020
    Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.
    Type: Application
    Filed: October 21, 2015
    Publication date: June 21, 2018
    Applicant: Merck Patent GmbH
    Inventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
  • Patent number: 9932403
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 3, 2018
    Assignee: Ablynx NV
    Inventors: Christine Knuehl, Bjoern Hock, Robert Hofmeister, Gerald Beste, Hilde Adi Pierrette Revets, Frank Kamiel Delphina Verdonck, Sigrid Godelieve Victor Cornelis
  • Publication number: 20170226199
    Abstract: The invention relates to anti-TNFa antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFa antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Application
    Filed: June 26, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Ralf GUENTHER, Stefan BECKER, Laura RHIEL, Bjoern HOCK, Christian SCHROETER
  • Publication number: 20160194380
    Abstract: The present invention pertains to highly potent Matriptase inhibitors derived from the miniprotein McotI-II.
    Type: Application
    Filed: April 8, 2014
    Publication date: July 7, 2016
    Applicant: Merck Patent GmbH
    Inventors: Michael TOMASZOWSKY, Niklas WEBER, Bernhard GLOTZBACH, Harald KOLMAR, Bjoern HOCK
  • Publication number: 20150337292
    Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterisation.
    Type: Application
    Filed: December 11, 2013
    Publication date: November 26, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Ralph GUENTHER, Bjoern HOCK, Stefan BECKER, Laura RHIEL
  • Patent number: 8969318
    Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: March 3, 2015
    Assignee: Merck Patent GmbH
    Inventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
  • Publication number: 20140039042
    Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
    Type: Application
    Filed: December 12, 2011
    Publication date: February 6, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
  • Publication number: 20130289259
    Abstract: Magnetic Resonance Imaging based on 19F instead of 1H opens up new diagnostic possibilities. The 19F nucleus has a high gyromagnetic ratio (40 MHz/T) and a natural isotopic abundance ratio of 100%. In the human body, 19F containing structures are exclusively present in the form of solid salts, e.g. teeth and bones. The J2 relaxation times of the endogenous 19F atoms are extremely short and the MR signal is hardly detectable. The lack of endogenous 19F-based structures with relatively high transverse relaxation times assures a very low background MR signal. Therefore, exogenous 19F-based MRI contrast agents allow for “hot spot” imaging in a way similar to other techniques such as PET. As a useful extension of its diagnostic use, MRI is also proposed for the monitoring of the delivery of bio-active agents such as therapeutic or diagnostic agents.
    Type: Application
    Filed: December 12, 2011
    Publication date: October 31, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Ralf Guenther, Bjoern Hock, Simon Goodman, Birgit Piater
  • Patent number: 8466200
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Publication number: 20130136748
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Application
    Filed: May 20, 2011
    Publication date: May 30, 2013
    Inventors: Christine Knuehl, Bjoern Hock, Robert Hofmeister, Gerald Beste, Hilde Adi Pierrette Revets, Frank Kamiel Delphina Verdonck, Sigrid Godelieve Victor Cornelis
  • Publication number: 20120172396
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: July 5, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK
  • Patent number: 8188288
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: May 29, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Patent number: 7981633
    Abstract: The present invention relates to methods for measuring the autophosphorylation of one or more tyrosine kinases and use of such methods in profiling kinase inhibitors and activators. As a representative example, the method comprises inducing kinase autophosphorylation activity in cells in presence and in absence of a kinase inhibitor, lysing the cells, capturing the tyrosine kinase in the cell lysate by adding a plurality of tyrosine kinase specific binding proteins which are associated with unique dyes, adding a phosphotyrosine specific antibody tagged with a marker which is distinguishable from the unique dyes, and identifying the autophosphorylated tyrosine kinase by detecting the unique dye and the marker. Alternately, the tyrosine kinases themselves could be coupled to the unique dyes. The present invention also relates to kits and compositions for carrying out the above-described methods.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: July 19, 2011
    Assignee: Merck Patent GmbH
    Inventors: Tanja Henzler, Bjoern Hock, Andree Blaukat, Uwe Hofmann